Dyslipidemias Pathophysiology, Evaluation and Management /
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted,...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Totowa, NJ :
Humana Press : Imprint: Humana Press,
2015.
|
| Σειρά: | Contemporary Endocrinology
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Lipoprotein Physiology
- Epidemiology of Blood Lipids and Lipoproteins
- Lipoprotein(a)
- Lipoproteins and Cardiovascular Disease Risk
- Detection and Treatment of Children and Adolescents with Dyslipidemia
- Type 2 Diabetes Mellitus and Dyslipidemia
- Type 1 Diabetes Mellitus and Dyslipidemia
- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome
- Dyslipidemia in HIV-infected Patients
- Monogenic Hypercholesterolemia
- Primary Hypertriglyceridemia
- Genetic Disorders of HDL Metabolism
- Sitosterolemia and Other Rare Sterol Disorders
- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia
- Drug-induced Dyslipidemia
- Lipodystrophies and Dyslipidemias
- Novel Genes for Dyslipidemias: Genome-Wide Association Studies
- Perspectives on Cholesterol Guidelines
- Nutrition and Coronary Heart Disease Prevention
- Phytosterol Therapy
- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease
- Polyphenols for Cholesterol Management
- Dietary Supplements for Cholesterol Management
- Statins: Risk-Benefits and Role in Treating Dyslipidemias
- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias
- Niacin: Risk-Benefits and Role in Treating Dyslipidemias
- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias
- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias
- Low Density Lipoprotein (LDL) Apheresis
- Novel Lipid Lowering Agents.
